表紙
市場調查報告書

中樞神經系統疾病的基因治療的全球市場:2019年∼2023年

Global Gene Therapy for CNS Disorders Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 823144
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
中樞神經系統疾病的基因治療的全球市場:2019年∼2023年 Global Gene Therapy for CNS Disorders Market 2019-2023
出版日期: 2019年03月28日內容資訊: 英文 119 Pages
簡介

特殊藥物指定的增加是未來幾年市場持續成長的關鍵因素之一。供應商為其新型基因療法接受特殊藥物指定,以幫助獲得更快的核準。部分市場相關人員,在其臨床研究中提供具有各種稅收優惠的孤兒藥品指定。因此,來自監管機構的特殊藥物指定數量的增加將推動基因治療在未來幾年中樞神經系統疾病市場的成長。Technavio的分析師預測,到2023年,中樞神經系統疾病市場的基因治療將達到近27%的年複合成長率。

本報告提供全球中樞神經系統疾病的基因治療市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 開發平台

第7章 市場區隔:各症狀

  • 市場區隔:各症狀
  • 各症狀比較:市場規模及預測(2018年∼2023年)
  • SMA
  • 其他
  • 市場機會:各症狀

第8章 客戶形勢

第9章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

第13章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics

第15章 附錄

  • 調查方法
  • 簡稱的清單

第16章 關於TECHNAVIO

目錄
Product Code: IRTNTR31112

About this market

The increase in special drug designations is one of the key factors anticipated to witness continuous growth in the forthcoming years. Vendors are receiving special drug designations for their novel gene therapies to help in receiving quicker approval. Some market players are even offering the orphan drug designation with various tax benefits on their clinical researches. As a result, the rising number of special drug designations from the regulatory bodies will drive the gene therapy for CNS disorders market growth in the forthcoming years. Technavio's analysts have predicted that the gene therapy for CNS disorders market will register a CAGR of nearly 27% by 2023.

Market Overview

Increase in special drug designations

One of the growth drivers of the global gene therapy for CNS disorders market is the increase in special drug designations. The increasing number of special drug designations from the regulatory bodies is expected to result in the quicker approval of gene therapy programs, which drives the growth of the market.

Uneven distribution of technology

One of the challenges in the growth of the global gene therapy for CNS disorders market is the Uneven distribution of technology. The lack of focus of major vendors on developing gene therapy for CNS disorders are expected to hinder the market growth during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the gene therapy for CNS disorders market during 019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Vendors in the market are developing advanced technologies that help in manufacturing gene therapies with superior efficacy for the treatment of various CNS indications. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY INDICATION

  • Market segmentation by indication
  • Comparison by indication
  • SMA - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by indication

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global gene therapy for CNS disorders market pipeline: Overview
  • Exhibit 18: Global gene therapy for CNS disorders market pipeline: Snapshot
  • Exhibit 19: Indication - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by indication
  • Exhibit 21: SMA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: SMA - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by indication
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: Biogen - Vendor overview
  • Exhibit 50: Biogen - Business segments
  • Exhibit 51: Biogen - Organizational developments
  • Exhibit 52: Biogen - Geographic focus
  • Exhibit 53: Biogen - Key offerings
  • Exhibit 54: Biogen - Key customers
  • Exhibit 55: bluebird bio, Inc. - Vendor overview
  • Exhibit 56: bluebird bio, Inc. - Product segments
  • Exhibit 57: bluebird bio, Inc. - Organizational developments
  • Exhibit 58: bluebird bio, Inc. - Key offerings
  • Exhibit 59: bluebird bio, Inc. - Key customers
  • Exhibit 60: Novartis AG - Vendor overview
  • Exhibit 61: Novartis AG - Business segments
  • Exhibit 62: Novartis AG - Organizational developments
  • Exhibit 63: Novartis AG - Geographic focus
  • Exhibit 64: Novartis AG - Segment focus
  • Exhibit 65: Novartis AG - Key offerings
  • Exhibit 66: Novartis AG - Key customers
  • Exhibit 67: Pfizer Inc. - Vendor overview
  • Exhibit 68: Pfizer Inc. - Business segments
  • Exhibit 69: Pfizer Inc. - Organizational developments
  • Exhibit 70: Pfizer Inc. - Geographic focus
  • Exhibit 71: Pfizer Inc. - Segment focus
  • Exhibit 72: Pfizer Inc. - Key offerings
  • Exhibit 73: Pfizer Inc. - Key customers
  • Exhibit 74: Voyager Therapeutics - Vendor overview
  • Exhibit 75: Voyager Therapeutics - Business segments
  • Exhibit 76: Voyager Therapeutics - Organizational developments
  • Exhibit 77: Voyager Therapeutics - Key offerings
  • Exhibit 78: Voyager Therapeutics - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
Back to Top